-
-
-
-
-
-
-
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
-
-
-
-
-
-
-
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
-
-
-
-
-
-
-
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
-
-
-
-
-
-
-
Supernus Announces Fourth Quarter and Full Year 2022 Financial Results
-
-
-
-
-
-
-
Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results
-
-
-
-
-
-
-
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer
-
-
-
-
-
-
-
Supernus Pharma (SUPN) Acquires Adamas Pharmaceuticals (ADMS) for $8.10/sh
-
1,202,254 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


